Peter C Farrell (Director) sold ~$503K of ResMed|
Planned saleWant the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Jan 7, 2026 · Filed Jan 9, 2026
The CEO of ResMed| sold $1.24M of ResMed| shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$1,240,065
Shares × reported transaction price
69 days after results of Oct 30, 2025, 22 days before results of Jan 29, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $248.21 on Jan 7, 2026, 21% above its 52-week low and 16% below its high, after a 1% drop over the previous 30 trading days
52-week range $204.54 (Apr 8, 2025) to $293.73 (Aug 22, 2025), 49% of the way up, from 250 adjusted closes. 30 trading days earlier: $250.75 on Nov 21, 2025. Describes the past only, not a forecast
RSI 51, 3% under its 200-day average, at its 50-day average, 16% below the 52-week high, 20-day volatility 17% a year, against the S&P 500: −4 points over 1 month, −15 points over 3 months, −14 points over 6 months
From the adjusted closes up to Jan 7, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +2.0% | −0.3% | +2.4% |
| 30 days | +9.3% | 0.0% | +9.3% |
| 90 days | −9.7% | −2.0% | −7.7% |
| 180 days | −18.5% | +7.4% | −25.9% |
Past results only. Not a forecast.
Peter C Farrell (Director) sold ~$503K of ResMed|
Planned saleMichael J Rider (Global General Counsel) sold ~$13K of ResMed|
Planned saleFund moves
38 tracked managers disclosed the same change for Q4 2025. From a 13F filed Feb 5, 2026 covering holdings at Dec 31, 2025 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.